Spermosens AB (publ) is listed on Spotlight Stockmarket. The share is traded under the ticker SPERM and ISIN-code SE0015346424.
Spotlight is an alternative market and does not have the same legal status as regulated market. Companies at Spotlight Stockmarket are subject to the rules of Spotlight and not the legal requirements for admission to trading on a regulated market. An investment in a company that is traded on Spotlight Stockmarket is riskier than an investment in a company that is traded on a regulated market.
Spermosens har som innehavare av “Seal of Excellence” från Europeiska unionens Horizon 2020, ännu en gång beviljats stöd för expansion och förstärkning av Bolagets patentportfölj från EU's prestigefyllda program IPA4SME.
Read more at CisionSpermosens AB meddelar idag att det Europapatentverket (EPO) slutgiltigt har godkänt patentet EP 3 768 825, som skyddar bolagets biosensor avsedd för användning inom In Vitro Fertilisering. Godkännandet följer det tidigare preliminära godkännande från EPO som meddelades den 16 april 2021.
Read more at CisionSpermosens AB meddelar idag att bolaget har anställt Ulrik Nilsson som CFO från 1 september 2021 och ersätter Cajsa Wramdemark som på konsultbasis innehar rollen idag.
Read more at Cision
Chairman of the board
Board member since: 2020
Born: 1964
Main occupation: Board professional
Shares: 30 000 direct
Options: 81 000 direct
Eva Nilsagård is currently the founder and CEO of Nilsagård Consulting AB. Eva holds an executive MBA in business management and organization as well as a master’s degree in accounting and finance from the Gothenburg School of Economics. Eva has been CFO at OptiGroup, Vitrolife and Plastal, SVP Strategy & Business development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva has a long experience of listed companies and over 10 years of experience as a mentor for young female managers.
Other current assignments: Nimbus Group AB, board member. Hansa Biopharma AB (publ), board member. Xbrane Biopharma AB, board member. Aktiebolaget Svensk Exportkredit, board member. IRRAS AB, board member. Addlife AB, board member. Bufab AB (publ), board member. Nilsagård Consulting AB, board member and CEO.
Board member
Board member since: 2019
Born: 1967
Main occupation: Embryologist and Unit Manager, Laboratory, Reproductive Medicine Centre, Skåne University Hospital
Shares: None
Options: None
Dr. Ingela Liljeqvist Soltic currently works as an embryologist and unit manager for laboratory and tissue establishment at the Center for Reproductive Medicine (RMC) at Skåne University Hospital. Ingela has a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science.Ingela has previously worked as an embryologist at IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience from IVF and fertility issues.
Board member
Board member since: 2020
Born: 1978
Main occupation: Investor and entrepreneur
Shares: 231 066 direct and via company
TO1: 75 066 direct and via company
Options: None
John Moll is the founder of Torna Kapital AB, through which he invests in development companies. John has conducted studies in finance at Lund University and master´s studies in biotechnology at Lund University. John has a long experience as an entrepreneur and has founded and sold two companies, including in the health and pharmaceutical sector. As an experienced Lund-based investor, John has a wide network of contacts in the Öresund region.
Other current assignments: Aktiebolaget Lundgren, Nilsson & Moll, board member. Carbiotix AB (publ), board member. Qlife Holding AB (publ), board member. Qlife Aps, board member. Huskvarna Stadshotell AB, board member. Town&Country Resorts AB, board member. Acantor Holding AB, board member. Torna Kapital AB, board member.
Board member
Board member since: 2020
Born: 1976
Main occupation: VP Sales & Marketing Galenica AB
Shares: 220 132 via company
TO1: 169 132 via company
Options: 27 000 direct
Sören Melsing Frederiksen currently holds the position of Vice President, Generics and Commercial Rx, ORIFARM GROUP A/S. Søren holds a B.A.Sc in Applied Science and a master´s degree in drug development. Søren has held several positions within LEO Pharma and as commercial manager for the Nordic region at Aspen Pharma. Søren has extensive experience in marketing and sales as well as the entire value chain in the pharmaceutical industry.
Other current assignments: VBM Ejendomsselkabet af 2007 Aps, board member. BotSupply ApS, board member. StenoCare A/S, board member. SML Holding ApS, board member and CEO. VBM LaboratorietA/S, board member.
Board member
Board member since: 2018
Born: 1991
Main occupation: CSO Spermosens AB
Shares: 1 578 240 direct
Options: None
Kushagr Punyani is founder and CSO for Spermosens AB. Kushagr holds a licentiate degree in engineering, microfluidic technology, from Lund University. From his studies in India together with Professor Sudha Srivastava, Punyani laid the foundation for Spermosens’ technology. Kushagr has also been involved in founding a number of companies that develop new technologies in medtech / pharmaceuticals.
Other current assignments: Diagonal Pharma AB, board member. Punyani Labs AB, board member.
CEO
Born: 1953
Shares: 140 284 direct
TO1: 35 524 direct
Options: 162 000 direct
John Lempert studied law at Lund University and is by the National Board of Health and Welfare a certified dental technician. John has among other worked for Johnson & Johnson in international positions and in smaller entrepreneurial companies being responsible for developing new patented dental materials from development, through regulatory affairs and manufacturing to completed market entry and build-up.
John has also had assignments for the World Bank and has more than 35 years of experience from business development in the medtech industry.
CFO
Born: 1977
Shares: 12 876 direct
TO1: 12 876 direct
Options: None
Cajsa Wramdemark, owner and founder of More than Finance AB, holds a Master of Science in International Business Administration and Economics from the School of Economics and Management, Lund University.
Cajsa has more than 20 years of experience within finance in both multi-national as well as SME companies within Life Science as well as other areas. She has had roles as CFO and Chief Accounting Manager. In addition to finance, Cajsa has been responsible for HR and Purchasing in previous roles.
At the Extraordinary General Meeting MAZARS AB was elected as auditor for Spermosens until the next Annual General Meeting.
Authorized Public Accountant (auktoriserad revisor) Bengt Ekenberg (born 1960) is the auditor in charge.
John Lempert
CEO, Spermosens AB
Lund, Sweden
Tel: +46 76 311 40 91
jsl@spermosens.com
Eminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
111 46 Stockholm
Tel: +46 8 684 211 00
info@eminova.se
